journal article·2025-03Open access

Intestine‐Decipher Engineered Capsules Protect Against Sepsis‐induced Intestinal Injury via Broad‐spectrum Anti‐inflammation and Parthanatos Inhibition

Yan Yan, Bin Li, Qiuxia Gao, Miao Wu, Hua Ma, Jiawei Bai, Chengtai Ma, Xinyu Xie, Yuan Gong, Lingqi Xu, Xiaoxue Li, Wei Wang, Yanqiu Wu, Jiamei Wang, Huanhuan Wang, Yi Feng, Yunlong Zhang, Peiran Li, Huimin Shi, Fei Ma, Yue Jia, Han Duan, Xinting Fu, Wenying Wang, Liying Zhan, Xianjin Du, Huiting Zhou, Yuhui Liao

Advanced Science· Volume 12· Issue 10

Abstract

Abstract Sepsis is a severe systemic inflammatory syndrome characterized by a dysregulated immune response to infection, often leading to high mortality rates. The intestine, owing to its distinct structure and physiological environment, plays a pivotal role in the pathophysiology of sepsis. It functions as the “central organ” or “engine” in the progression of sepsis, with intestinal injury exacerbating the condition. Despite the availability of current therapies that offer partial symptom relief, they fall short of adequately protecting the intestinal barrier. In this study, an advanced nanodrug formulation (OLA@MΦ NPs) is developed by coating macrophage membranes onto polymeric organic nanoparticles encapsulating olaparib. When loaded into pH‐responsive capsules, an intestine‐decipher engineered capsule (cp‐OLA@MΦ NPs) is successfully formulated. Upon oral administration in septic mice, these capsules withstand gastric acid and release their contents in the intestine, specifically targeting injured tissues. The released OLA@MΦ NPs effectively neutralize pro‐inflammatory cytokines via macrophage membrane receptors, while olaparib inhibits intestinal epithelial parthanatos (a form of programmed cell death) by suppressing poly(ADP‐ribose) polymerase 1 (PARP1) activation. This strategy significantly reduces bacterial translocation, slows the progression of sepsis, and enhances survival in septic mice, thus presenting a promising therapeutic approach for sepsis in clinical applications.
Source: crossref · Quality: baseline

Research context

OpenAlex topics: Intensive Care Unit Cognitive Disorders · Immune Response and Inflammation · Sepsis Diagnosis and Treatment

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Department of Critical Care Medicine Renmin Hospital of Wuhan University Wuhan 430060 China

School of Inspection Ningxia Medical University Yinchuan Ningxia 750004 China

Institute for Engineering Medicine Kunming Medical University Kunming 650500 China

Institute of Pediatric Research Children's Hospital of Soochow University Suzhou 215025 China

Molecular Diagnosis and Treatment Center for Infectious Diseases Dermatology Hospital of Southern Medical University Guangzhou Guangdong 510091 China

Department of Microbiology School of Public Health Southern Medical University Guangzhou 510515 China

Funding

National Key Research and Development Program of China · National Natural Science Foundation of China · Basic and Applied Basic Research Foundation of Guangdong Province · Natural Science Foundation of Hubei Province

References (83)

Show source-provided references
1. 10.1097/CCM.000000000000533710.1097/CCM.0000000000005337 ↗
2. 10.1016/S0140-6736(19)32989-710.1016/S0140-6736(19)32989-7 ↗
3. 10.3389/fimmu.2019.0089110.3389/fimmu.2019.00891 ↗
4. 10.1016/j.bbadis.2017.03.00510.1016/j.bbadis.2017.03.005 ↗
5. 10.1186/s13054-022-04090-110.1186/s13054-022-04090-1 ↗
6. 10.1016/j.chom.2024.08.00710.1016/j.chom.2024.08.007 ↗
7. 10.1016/j.bbadis.2017.03.00510.1016/j.bbadis.2017.03.005 ↗
8. 10.1001/archsurg.1986.0140002008201010.1001/archsurg.1986.01400020082010 ↗
9. 10.1186/s13054-020-02989-110.1186/s13054-020-02989-1 ↗
10. 10.1093/burnst/tkab03610.1093/burnst/tkab036 ↗
11. 10.1038/s41401-024-01238-310.1038/s41401-024-01238-3 ↗
12. 10.1073/pnas.221787712110.1073/pnas.2217877121 ↗
13. 10.1097/CCM.000000000000533710.1097/CCM.0000000000005337 ↗
14. 10.2147/IJN.S39454410.2147/IJN.S394544 ↗
15. 10.1111/cns.1477810.1111/cns.14778 ↗
16. 10.1038/s41420-024-01880-010.1038/s41420-024-01880-0 ↗
17. 10.1016/j.bcp.2024.11617410.1016/j.bcp.2024.116174 ↗
18. 10.1186/s40478-023-01697-510.1186/s40478-023-01697-5 ↗
19. 10.1016/j.lfs.2020.11897510.1016/j.lfs.2020.118975 ↗
20. 10.1016/j.bcp.2024.11617410.1016/j.bcp.2024.116174 ↗
21. 10.1016/j.ejphar.2024.17676510.1016/j.ejphar.2024.176765 ↗
22. 10.1038/s41419-023-05581-x10.1038/s41419-023-05581-x ↗
23. 10.1371/journal.pbio.300145510.1371/journal.pbio.3001455 ↗
24. 10.1016/j.jid.2024.04.02010.1016/j.jid.2024.04.020 ↗
25. 10.1016/j.biopha.2023.11580210.1016/j.biopha.2023.115802 ↗
26. 10.1177/1557988321102945810.1177/15579883211029458 ↗
27. 10.3390/antiox1303034310.3390/antiox13030343 ↗
28. 10.7150/ijbs.9456810.7150/ijbs.94568 ↗
29. 10.7150/ijbs.9456810.7150/ijbs.94568 ↗
30. 10.1016/j.breast.2024.10378910.1016/j.breast.2024.103789 ↗
31. 10.1002/iju5.1276610.1002/iju5.12766 ↗
32. 10.1038/s41565-024-01618-010.1038/s41565-024-01618-0 ↗
33. 10.1002/adma.20230537810.1002/adma.202305378 ↗
34. 10.1186/s12951-021-01128-410.1186/s12951-021-01128-4 ↗
35. 10.1073/pnas.171426711410.1073/pnas.1714267114 ↗
36. 10.7150/thno.8152010.7150/thno.81520 ↗
37. 10.1016/j.fsi.2018.07.04810.1016/j.fsi.2018.07.048 ↗
38. 10.1186/s12951-021-01128-410.1186/s12951-021-01128-4 ↗
39. 10.1073/pnas.171426711410.1073/pnas.1714267114 ↗
40. 10.7150/thno.8152010.7150/thno.81520 ↗
41. 10.3389/fmicb.2024.141527410.3389/fmicb.2024.1415274 ↗
42. 10.1186/s13054-021-03862-510.1186/s13054-021-03862-5 ↗
43. 10.1021/acsnano.0c0380710.1021/acsnano.0c03807 ↗
44. 10.3390/antiox1203065910.3390/antiox12030659 ↗
45. 10.1016/j.burns.2016.09.02310.1016/j.burns.2016.09.023 ↗
46. 10.3390/antiox1101008810.3390/antiox11010088 ↗
47. 10.1021/acsnano.0c0380710.1021/acsnano.0c03807 ↗
48. 10.1021/acsnano.0c0380710.1021/acsnano.0c03807 ↗
49. 10.1016/j.biopha.2023.11580210.1016/j.biopha.2023.115802 ↗
50. 10.1038/s41467-019-11169-x10.1038/s41467-019-11169-x ↗
51. 10.1016/j.biopha.2023.11580210.1016/j.biopha.2023.115802 ↗
52. 10.1016/j.biopha.2023.11580210.1016/j.biopha.2023.115802 ↗
53. 10.3390/ijms2313729210.3390/ijms23137292 ↗
54. 10.1016/j.arr.2021.10126310.1016/j.arr.2021.101263 ↗
55. 10.3389/fimmu.2019.0089110.3389/fimmu.2019.00891 ↗
56. 10.3389/fmicb.2024.138533310.3389/fmicb.2024.1385333 ↗
57. 10.1021/acs.jafc.0c0057310.1021/acs.jafc.0c00573 ↗
58. 10.3390/microorganisms1203046310.3390/microorganisms12030463 ↗
59. 10.1016/j.jep.2023.11650510.1016/j.jep.2023.116505 ↗
60. 10.1016/j.phymed.2024.15552310.1016/j.phymed.2024.155523 ↗
61. 10.1016/j.freeradbiomed.2021.10.02610.1016/j.freeradbiomed.2021.10.026 ↗
62. 10.1016/j.bioactmat.2024.04.01310.1016/j.bioactmat.2024.04.013 ↗
63. 10.1002/advs.20240333710.1002/advs.202403337 ↗
64. 10.3390/ijms2216888210.3390/ijms22168882 ↗
65. 10.1016/j.bioactmat.2024.04.01310.1016/j.bioactmat.2024.04.013 ↗
66. 10.1016/j.ejim.2023.10.03210.1016/j.ejim.2023.10.032 ↗
67. 10.1186/cc1310610.1186/cc13106 ↗
68. 10.1016/j.intimp.2024.11273210.1016/j.intimp.2024.112732 ↗
69. 10.1186/cc510210.1186/cc5102 ↗
70. 10.3390/antiox1307076410.3390/antiox13070764 ↗
71. 10.1097/CCM.000000000000533710.1097/CCM.0000000000005337 ↗
72. 10.3389/fimmu.2019.0089110.3389/fimmu.2019.00891 ↗
73. 10.1016/j.bbadis.2017.03.00510.1016/j.bbadis.2017.03.005 ↗
74. 10.1186/s13054-020-02989-110.1186/s13054-020-02989-1 ↗
75. 10.1093/burnst/tkab03610.1093/burnst/tkab036 ↗
76. 10.1097/CCM.000000000000533710.1097/CCM.0000000000005337 ↗
77. 10.2147/IJN.S39454410.2147/IJN.S394544 ↗
78. 10.1111/cns.1477810.1111/cns.14778 ↗
79. 10.1038/s41420-024-01880-010.1038/s41420-024-01880-0 ↗
80. 10.1073/pnas.171426711410.1073/pnas.1714267114 ↗
81. 10.1186/s13054-022-04090-110.1186/s13054-022-04090-1 ↗
82. 10.1016/j.chom.2024.08.00710.1016/j.chom.2024.08.007 ↗
83. 10.1016/j.fsi.2018.07.04810.1016/j.fsi.2018.07.048 ↗